relevant cell types
advanced cell therapies
monitoring of cell grafts
therapeutic scale cell production
novel cell monitoring tools
improved cell delivery
universal cell source
endothelial cells
connective tissue
innovative bioreactor technologies
innovative medical technologies
irreversible loss of heart muscle tissue
TECHNOBEAT’s consortium of leading European stem cell researchers
hEArt Therapies Cardiovascular diseases
Human induced pluripotent stem cells
clinical translation of cardiac µ-tissue
hiPSCs
end-stage heart failure
relevant preclinical models of cellular heart repair
MI patients
application of tools
reprogramming patients’ somatic cells
organ repair
TECHNOBEAT’s ultimate objectives
robust therapeutic scale production of hiPSC
functional integration
suffering patients
derived progenies
organ transplantation
ambitious objectives
regulatory compliant bioprocessing of innovative iPSC
new treatment options
functional reconstitution of damaged hearts
differentiation potential
clinicians
GMP standards
line
Europe’s attractiveness
major socio-economic burden
myocardial infarction
cardiomyocytes
pericytes
Breakthrough
unlimited expandability
safety
hub
bone marrow
blood
interdisciplinary excellence
technical- engineers
global healthcare
concept
proof
development
reasonable cost
industry
academia
contrast
adult